Several ACTA Member organisations including the Australasian Lung Cancer Trials Group and the Australasian Leukaemia and Lymphoma Group have endorsed an interim consensus guide for managing immunocompromised oncology and haematology patients during the COVID-19 pandemic.
The guidance covers:
- Risk factors for severe COVID-19 disease
- Considerations for cancer patients who contract COVID-19 disease or develop symptoms of COVID-19 disease
- Actions to consider phased according to the presence or absence of community transmission of COVID-19 disease and capacity of healthcare services
- Suggested patient communications
The publication emphasises the need for proportionate, equitable and transparent measures and includes considerations for radiation oncology, clinical trial participation, palliative care and supportive care.